MetaCap

Enliven Therapeutics (ELVN) vs Viridian Therapeutics (VRDN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enliven Therapeutics (ELVN) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 113.9% versus a loss of 1.3%. Over five years, ELVN leads with a +254.6% price change compared with +63.7% for VRDN. Enliven Therapeutics is the larger company by market cap ($3.42 billion vs $3.40 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELVN+113.93%VRDN-1.25%
+193%+62%-68%
Nov 21, 20251 yearNov 20, 2026
ELVN+252.50%VRDN+54.04%
+379%+145%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELVN versus VRDN key metrics
MetricELVNVRDN
Share price$46.53$29.96
Market cap$3.42B$3.40B
1-day change+0.26%-4.71%
YTD return+202.14%-3.73%
1-year return+113.93%-1.25%
5-year return+254.65%+63.72%
EPS (TTM)$-1.69$-3.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$70.85M
Revenue growth (YoY)—+23359.93%
Net income (latest FY)$-103.69M$-342.60M
Operating margin—-512.91%
Net margin—-483.57%
52-week high$62.32$34.29
52-week low$14.79$13.18
Distance from 52-week high-25.34%-12.63%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+59.75%+42.72%
Average volume1.36M2.14M
Shares outstanding73.60M113.56M
Employees65252
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELVN has outperformed VRDN by 115.2 percentage points over the past year.

About Enliven Therapeutics

ELVN stock →

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Viridian Therapeutics

VRDN stock →

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees

ELVN vs VRDN FAQ

Which is bigger, Enliven Therapeutics or Viridian Therapeutics?

Enliven Therapeutics (ELVN) is larger, with a market capitalization of $3.42B compared with $3.40B for Viridian Therapeutics (VRDN).

Which stock has performed better over the past year, ELVN or VRDN?

ELVN returned +113.93% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.

Are Enliven Therapeutics and Viridian Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons